Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exelon Patch in Severe Alzheimer's Dementia
NCT02989402Phase 4Completed
- Sponsor
- Novartis
- Start
- Dec 2018
- Primary completion
- Dec 2022
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rivastigmine in Alzheimer's disease (AD), sponsored by Novartis. Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) at 16 weeks. Started Dec 2018; status: completed.
02
Drugs
rivastigmine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02989402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02989402.